No Picture
Trading Ideas

Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise

Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients. The company said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to chemotherapy alone in patients with advanced non-small cell lung cancer, the most common form of the disease. Data presented at a medical meeting last month showed that about 40% of patients with advanced lung cancer on the Opdivo-Yervoy combination were alive after two years, …read more […]

No Picture
Trading Ideas

COLUMN-Sustainability the new battleground for aluminium producers: Andy Home

The U.S. aluminium producer has just announced a five-year review of around 4.0 million tonnes of alumina capacity and 1.5 million tonnes of smelter capacity. It’s not quite an annual event but Alcoa shareholders have been here many times before as the company keeps trying to move down the cost curve in the face of chronically depressed prices. On the London Metal Exchange (LME) three-month aluminium has ground steadily lower over the course of 2019 and at a current $1,720 per tonne is close to the near three-year low of $1,705 recorded earlier this month. …read more […]